KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure

The KEYNOTE-013 study was conducted to evaluate pembrolizumab monotherapy in hematologic malignancies; classical Hodgkin lymphoma (cHL) was an independent expansion cohort. We present long-term results based on >4 years of median follow-up for the cHL cohort. The trial enrolled cHL patients who e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Armand, Philippe, Kuruvilla, John, Michot, Jean-Marie, Ribrag, Vincent, Zinzani, Pier Luigi, Zhu, Ying, Marinello, Patricia, Nahar, Akash, Moskowitz, Craig H.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7322954/
https://ncbi.nlm.nih.gov/pubmed/32556281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001367
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars